Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jul-Aug;37(4):1894-1900.
doi: 10.21873/invivo.13283.

Evaluation of Chemotherapy-induced Dysgeusia in Patients With Gastrointestinal Cancer: A Pilot Study

Affiliations

Evaluation of Chemotherapy-induced Dysgeusia in Patients With Gastrointestinal Cancer: A Pilot Study

Shigeyuki Nagata et al. In Vivo. 2023 Jul-Aug.

Abstract

Background/aim: Dysgeusia, one of the adverse effects of cancer chemotherapy, and anorexia due to taste disorder can significantly impair the quality of life of patients. However, an evaluation method for dysgeusia has not yet been established. The present prospective study aimed to utilize a combination of subjective and objective assessment methods to evaluate dysgeusia in patients with gastrointestinal cancer initiating chemotherapy, to determine chemotherapeutic drugs and regimens causing dysgeusia, and to assess whether dysgeusia was associated with zinc deficiency.

Patients and methods: A total of 21 patients with newly diagnosed gastrointestinal cancer were registered between August 2020 to March 2021. The following regimens were also included in the evaluation if the patients did not develop dysgeusia. A total 30 regimens were administered to the patients during the study period. A salt-impregnated test paper (Salsave®) was used as a subjective assessment, and the chemotherapy-induced taste alteration scale was used as an objective assessment.

Results: Based on physician interviews, dysgeusia was diagnosed in 8 of 21 patients (38%) treated with 8 of 30 regimens (27%). All regimens that resulted in dysgeusia contained platinum-based drugs. The patients who developed dysgeusia had higher controlling nutritional status scores at the start of chemotherapy compared to those who did not develop dysgeusia. In both subjective and objective assessments, the patients with dysgeusia performed significantly worse than those without dysgeusia. Six of the eight patients who developed dysgeusia were administered Novelzine, which did not improve the taste disorder despite the improvement of serum zinc levels.

Conclusion: The combined approach using subjective and objective taste assessment methods was useful in assessing chemotherapy-induced dysgeusia. Mechanisms other than hypozincemia should be considered as contributors to taste disorders caused by platinum-based drugs.

Keywords: Chemotherapy-induced dysgeusia; CiTAS; paper testing; serum zinc; taste test.

PubMed Disclaimer

Conflict of interest statement

The Authors declare that there are no conflicts of interest regarding the publication of this paper.

Similar articles

References

    1. Bernhardson B, Tishelman C, Rutqvist L. Self-reported taste and smell changes during cancer chemotherapy. Supportive Care in Cancer. 2019;16(3):275–283. doi: 10.1007/s00520-007-0319-7. - DOI - PubMed
    1. Wickham RS, Rehwaldt M, Kefer C, Shott S, Abbas K, Glynn-Tucker E, Potter C, Blendowski C. Taste changes experienced by patients receiving chemotherapy. Oncol Nurs Forum. 1999;26(4):697–706. - PubMed
    1. U.S. Department of Health and Human Services, National Institutes of Health National Cancer Institute: Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0, 2017. Available at: https://www.eortc.be/services/doc/ctc/ [Last accessed on May 20, 2023]
    1. Holmes S. Food avoidance in patients undergoing cancer chemotherapy. Supportive Care in Cancer. 2023;1(6):326–330. doi: 10.1007/BF00364971. - DOI - PubMed
    1. Boltong A, Keast R, Aranda S. Experiences and consequences of altered taste, flavour and food hedonics during chemotherapy treatment. Supportive Care in Cancer. 2019;20(11):2765–2774. doi: 10.1007/s00520-012-1398-7. - DOI - PubMed

LinkOut - more resources